Adrenocortical Carcinoma Drug Pipeline — PatSnap Eureka
Adrenocortical Carcinoma Drug Pipeline: Mitotane, EDP-M & Kinase Inhibitors
ACC affects fewer than 2 people per million annually, yet its 5-year survival rate in metastatic disease falls below 15%. PatSnap Eureka synthesizes 80+ patent and literature records to map every emerging therapeutic approach — from mitotane combinations to next-generation targeted kinase inhibitors.
Key Molecular Target Prevalence in ACC
Frequency of oncogenic drivers across ACC tumor samples from retrieved literature
ACC Drug Pipeline: Six Therapeutic Approaches Across Development Stages
From the only FDA-approved agent to emerging antigen-based immunotherapy, the ACC pipeline spans approved, clinical, and preclinical stages — all mapped from 80+ retrieved patent and literature records.
Mitotane Monotherapy & Adjuvant Use
Mitotane (o,p'-DDD), the only FDA-approved drug for ACC, works via adrenocortical cytolysis, inhibition of steroidogenic cytochromes P450, and apoptosis induction. A therapeutic plasma threshold of ≥14 mg/L is the established target, though achieving it takes a median of 8 months in adjuvant patients. The ADIUVO trial is evaluating adjuvant mitotane in low-intermediate risk patients.
FDA ApprovedEDP-M Combination Chemotherapy Regimen
Etoposide + Doxorubicin + Cisplatin + Mitotane (EDP-M) is the reference first-line regimen for advanced/metastatic ACC from the FIRM-ACT trial. In 58 consecutively treated patients, EDP-M achieved 50% partial response, median PFS of 10.1 months, and median OS of 18.7 months. A key pharmacokinetic liability: mitotane's CYP3A4 induction accelerates etoposide clearance, potentially contributing to chemoresistance.
Established Standard of CareTargeted Kinase Inhibitors
Multiple kinase inhibitor classes show activity in ACC models: IGF-1R inhibitors (linsitinib/OSI-906), CDK4/6 inhibitors, multi-kinase inhibitors (sunitinib, sorafenib), nilotinib (more cytotoxic than mitotane in spheroid cultures), and dual EGFR+IGF1R co-inhibition. One Phase I clinical trial (cixutumumab + temsirolimus, 26 patients at MD Anderson) yielded limited efficacy in heavily pre-treated patients.
Predominantly PreclinicalImmune Checkpoint Inhibitors
Five clinical trials evaluate four agents: pembrolizumab, avelumab, nivolumab, and ipilimumab. The JAVELIN Phase 1b (n=50) reported ORR of 6% with 42% stable disease. Nivolumab + ipilimumab dual checkpoint blockade is the first reported combination immunotherapy trial in ACC. A critical barrier: cortisol hypersecretion drives immunosuppression, creating significantly greater immunoresistance in cortisol-secreting tumors.
Phase 1b / ClinicalAntigen-Based Immunotherapy
An active European patent (Enterome S.A., EP 2025) describes polypeptide/peptide vaccine-based immunotherapy targeting IL-13Rα2, BIRC5, and FOXM1 epitopes for adrenal cancers. The biological rationale is supported by FDA Center for Biologics data showing high IL-13Rα2 gene expression correlates with adverse clinical outcome in ACC patients.
Active Patent · EP 2025Alternative Chemotherapy Combinations
Gemcitabine + capecitabine (Gem/Cape) is the most established second-line option, with 30% clinical benefit rate at 4 months, median PFS of 3 months, and median disease-specific survival of 8 months in 50 consecutive patients. Additional strategies include paclitaxel + carboplatin + mitotane and a Phase I-evaluated imatinib + dacarbazine + capecitabine combination at MD Anderson (20 patients).
Second-Line Clinical UseThe Molecular Landscape Driving ACC Drug Discovery
Adrenocortical carcinoma is defined by a cluster of recurrently dysregulated oncogenic pathways, each representing a distinct therapeutic vulnerability. PatSnap's IP analytics platform enables researchers to cross-reference patent filings against published genomic profiling data to identify which targets have active commercial development programs.
The IGF2/IGF1R axis is the most consistently amplified oncogenic driver in the retrieved dataset, with IGF2 overexpressed in 95% of ACC cases. Downstream activation of both the PI3K/AKT/mTOR and MAPK/ERK axes explains why dual IGF-1R/mTOR blockade (cixutumumab + temsirolimus) was clinically evaluated, though a 26-patient Phase I trial yielded limited efficacy — suggesting pathway redundancy or patient selection barriers remain unresolved.
CDK4 is overexpressed more than 2-fold in 62% of ACC samples by RT-qPCR, with protein-level confirmation in 104 ACC samples. The NCI Developmental Therapeutics Branch screened 4,991 compounds across ACC cell lines and identified MELK (maternal embryonic leucine zipper kinase) inhibitors and CDK inhibitors as top candidates, with synergistic efficacy validated in spheroid formation and clonogenicity assays.
HSP90 is expressed at elevated levels in ACC tumor samples relative to benign adrenocortical tumors. Researchers at Hôpital Cochin, Paris tested five HSP90 inhibitors (including 17-AAG, luminespib, and ganetespib) across multiple ACC cell lines, establishing HSP90 as both a druggable target and a prognostic marker. The PatSnap life sciences intelligence suite enables teams to track such emerging targets across patent and literature simultaneously.
ZNRF3 and ATRX low protein expression are associated with decreased overall survival in 82 adult ACC patients (ATRX: HR 0.521, p=0.049; ZNRF3: HR 0.441, p=0.015), establishing them as novel negative prognostic markers with potential therapeutic relevance.
ACC Treatment Outcomes: EDP-M, Second-Line, and Immunotherapy
Quantitative outcome data from the retrieved clinical literature, spanning first-line chemotherapy, second-line regimens, and checkpoint inhibitor trials in metastatic ACC.
EDP-M vs. Gem/Cape: Comparative Survival Outcomes
Median PFS and OS for first-line EDP-M (n=58, Brescia) vs. second-line Gem/Cape (n=50, Brescia) in metastatic ACC patients
Checkpoint Inhibitor Response in Metastatic ACC
JAVELIN Phase 1b avelumab trial (n=50): objective response rate 6%, stable disease 42%, progressive/other 52%
EDP-M: Pharmacology, Liabilities, and Emerging Combinations
The reference first-line regimen for advanced ACC carries significant pharmacokinetic liabilities — and new combination signals are emerging from case-report-level evidence.
CYP3A4 Induction: The Core PK Liability
Mitotane's potent induction of CYP3A4 significantly accelerates etoposide clearance, reducing etoposide plasma AUC in the EDP-M regimen. A French pilot study documented this interaction and proposed dose escalation of etoposide as a compensatory strategy to address potential chemoresistance driven by this pharmacokinetic interaction.
Supportive Care Protocol for EDP-M Toxicity
A detailed supportive care protocol from the University of Brescia includes use of adrenal steroidogenesis inhibitors (e.g., metyrapone) for rapid Cushing syndrome control in hormonally active ACC, and strategies for managing EDP-M in frail or renally impaired patients — essential for real-world implementation of this complex regimen.
Kinase Inhibitor Activity in Adrenocortical Carcinoma: Agent-by-Agent Summary
Preclinical and clinical evidence for kinase inhibitor classes in ACC, drawn from retrieved patent and literature records. PatSnap Analytics enables landscape mapping across all these agent classes simultaneously.
| Agent / Class | Target(s) | Evidence Level | Key Finding from Retrieved Records | Stage |
|---|---|---|---|---|
| Linsitinib (OSI-906) | IGF-1R / InsR | Patent (EP 2012, inactive) + preclinical | OSI Pharmaceuticals patent asserts use for ACC; grounded in IGF2 overexpression in 95% of cases | Preclinical / Patent |
| Cixutumumab + Temsirolimus | IGF-1R + mTOR | Phase I (n=26, MD Anderson) | Feasible but limited efficacy in heavily pre-treated metastatic ACC patients | Phase I |
| Sunitinib | VEGFR / PDGFR / c-KIT | Preclinical (NCI-H295 & SW13 cell lines) | Dose-dependent reduction in cell viability; VEGFR2 expressed in 99% of ACC samples | Preclinical |
| Sorafenib | Multi-kinase (RAF, VEGFR, PDGFR) | Preclinical (H295R cells, 3D culture) | Apoptosis induction and disruption of VE-cadherin/β-catenin complex formation in H295R cells | Preclinical |
| Nilotinib | BCR-ABL / c-KIT / PDGFR | Preclinical (spheroid cultures, patient-derived ACC-T36) | More cytotoxic than mitotane in ACC spheroid cultures; nilotinib + mitotane combination also evaluated | Preclinical |
| Erlotinib + NVP-AEW541 | EGFR + IGF1R | Preclinical (H295R, SW13 + xenograft) | Synergistic anti-ACC activity; EGFR expressed in 66.67%, IGF1R in 80% of ACC samples | Preclinical |
| MELK inhibitors + CDK inhibitors | MELK / CDK | Preclinical (NCI 4,991-compound screen) | Top hits from NCI high-throughput screen; synergy validated in spheroid formation and clonogenicity assays | Preclinical |
Map the full kinase inhibitor patent landscape for ACC
PatSnap Eureka searches patents, clinical trials, and literature across all these agent classes in a single query
Who Is Driving ACC Drug Discovery? Assignee & Institution Analysis
In this dataset, activity is exclusively literature-driven (academic papers), with two patent filings retrieved. No large pharma company dominates — academic and public cancer research institutions account for the overwhelming majority of records.
National Cancer Institute / NIH
Among the most active institutions in the dataset. Contributions include molecular profiling, high-throughput drug screening (the 4,991-compound MELK/CDK screen and a 2,816-compound repurposing screen), and targeted therapy reviews — reflecting NCI's rare tumor research programs.
High-throughput screening · Rare tumorsUniversity of Turin / San Luigi Gonzaga Hospital
Highly represented across retrieved results, contributing to mitotane mechanism of action, pharmacokinetics, adjuvant duration, CYP enzyme studies (including CYP2W1 biomarker work), and mitotane resistance modeling. One of the leading European clinical and translational research centers for ACC.
Mitotane pharmacology · CYP enzymesUniversity of Brescia / ASST Spedali Civili
Multiple contributions on EDP-M regimen outcomes (58-patient cohort), supportive care protocols, second-line Gem/Cape (50-patient cohort), and immunotherapy resistance. A leading Italian referral center with strong real-world clinical outcomes data across multiple treatment lines.
EDP-M outcomes · Second-line dataOSI Pharmaceuticals & Enterome S.A.
Two commercial patent assignees retrieved. OSI Pharmaceuticals holds an inactive EP patent (2012) for linsitinib (OSI-906) in ACC. Enterome S.A. holds an active EP patent (2025) claiming antigen-based immunotherapy targeting IL-13Rα2, BIRC5, and FOXM1 epitopes — the sole contemporary active commercial IP signal in this dataset. PatSnap customers track such competitive IP signals in real time.
Active patent: Enterome EP 2025Active Clinical Trials & Key Evidence-Generation Efforts in ACC
Retrieved results document six explicit clinical signals across the ACC pipeline. The ADIUVO randomized controlled trial is the key ongoing adjuvant therapy evidence-generation effort, evaluating mitotane versus observation in low-intermediate risk ACC patients — with emerging data referenced in a 2022 paper.
The FIRM-ACT trial established EDP-M as the first-line standard, referenced indirectly via EDP-M's description as the "reference regimen" across multiple retrieved results. At MD Anderson, the life sciences research platform supports tracking of Phase I dose-escalation data for imatinib + dacarbazine + capecitabine in advanced endocrine cancers including ACC (20 patients enrolled, recommended Phase II dose defined).
Immunotherapy clinical evidence is anchored by two key trials: the JAVELIN Phase 1b avelumab cohort (n=50, ORR 6%, stable disease 42%) and the CA209-538 nivolumab + ipilimumab subgroup analysis from the Olivia Newton-John Cancer Research Institute — the first reported dual checkpoint blockade trial in ACC. PatSnap Analytics enables competitive intelligence teams to monitor trial status updates across all these programs simultaneously.
A critical mechanistic barrier documented across immunotherapy results is cortisol hypersecretion-driven immunosuppression. Vanderbilt University Medical Center's multiplatform integrative analysis demonstrates significantly greater immunoresistance in cortisol-secreting ACC versus non-cortisol-secreting tumors — a finding with direct implications for patient selection in future immunotherapy trials. The NIH and EMA both recognize ACC as an area of unmet medical need warranting orphan drug designation consideration.
Adrenocortical Carcinoma Drug Pipeline — key questions answered
EDP-M (etoposide, doxorubicin, cisplatin, and mitotane) is consistently described as the reference first-line chemotherapy regimen for advanced/metastatic ACC, emerging from the FIRM-ACT trial. In a Brescia reference center series of 58 consecutively treated patients, EDP-M achieved a partial response in 50% of patients, with a median progression-free survival of 10.1 months and median overall survival of 18.7 months.
A therapeutic plasma threshold of ≥14 mg/L is consistently cited as the target concentration, with multiple retrieved pharmacokinetic studies documenting the difficulty and delay (median 8 months in one Italian multicenter cohort of 110 adjuvant patients) in achieving this target.
Retrieved results converge on several recurrently dysregulated pathways: IGF2 overexpression in 95% of ACC cases, TP53 mutations in 20–34% of samples, CTNNB1/Wnt pathway activating mutations in 10–13% of cases, CDK4 overexpression in 62% of ACC tumor samples, and VEGF/VEGFR2 expressed in 72% and 99% of ACC samples respectively.
A Phase 1b JAVELIN expansion cohort (n=50 mACC patients) reported an objective response rate (ORR) of 6.0% (3 partial responses), with 42% stable disease. Continuation of mitotane was permitted in 50% of patients.
A critical mechanistic barrier identified across retrieved immunotherapy results is cortisol hypersecretion-driven immunosuppression. Retrieved results from Vanderbilt University Medical Center characterize the tumor microenvironment of cortisol-secreting ACC and demonstrate significantly greater immunoresistance versus non-cortisol-secreting tumors.
Gemcitabine plus capecitabine (Gem/Cape) is described as a frequently adopted second-line chemotherapy for metastatic ACC, with a clinical benefit rate of 30% at 4 months (partial response plus stable disease), median PFS of 3 months, and median disease-specific survival of 8 months in 50 consecutive patients.
Still have questions? Let PatSnap Eureka search the ACC patent and literature database for you.
Ask PatSnap Eureka About ACCAccelerate Your ACC Drug Discovery Research
Join 18,000+ innovators already using PatSnap Eureka to map rare oncology pipelines, identify emerging targets, and monitor competitive IP signals across patent and literature simultaneously.
References
- Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target — University of Würzburg (2020)
- Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies — Foundation Medicine (2014)
- Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options — University Hospital Münster (2022)
- Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies — University of Turin (2021)
- Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment — University of Catania (2019)
- Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma — Reims University Hospitals (2019)
- Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience — University of Brescia (2020)
- Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study — Institut Cochin, Paris (2018)
- Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen — University of Brescia (2022)
- EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report — Shuguang Hospital, Shanghai (2022)
- Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma — MD Anderson Cancer Center (2013)
- Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer — NCI/NIH (2022)
- Sunitinib inhibits cell proliferation and alters steroidogenesis — University of Würzburg (2011)
- Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer — Sapienza University of Rome (2021)
- The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids — University of São Paulo (2018)
- Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma — Ruijin Hospital, Shanghai Jiaotong University (2016)
- Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial — EMD Serono (2018)
- Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538 — Olivia Newton-John Cancer Research Institute (2021)
- Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane — American University of Beirut Medical Center (2021)
- Multiplatform Integrative Analyses of Immunosuppressive Signatures in Cortisol-secreting Adrenocortical Carcinoma — Vanderbilt University Medical Center (2021)
- Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy — University of Brescia (2021)
- Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma — Hôpital Cochin, Paris (2019)
- CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma — University of Turin (2014)
- Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation — Fudan Institute of Urology (2018)
- IL-13Rα2 gene expression is a biomarker of adverse outcome in patients with adrenocortical carcinoma — US FDA (2021)
- Low Protein Expression of both ATRX and ZNRF3 as Novel Negative Prognostic Markers of Adult Adrenocortical Carcinoma — University of São Paulo (2021)
- A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers — MD Anderson Cancer Center (2014)
- ClinicalTrials.gov — ADIUVO Trial and ACC Clinical Trial Registry
- National Institutes of Health (NIH) — Rare Tumor Research Programs
- European Medicines Agency (EMA) — Orphan Designation for Adrenocortical Carcinoma
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research literature to answer instantly.